| P2093 | author name string | Kitler ME | |
| P2860 | cites work | Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 |
| | Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics | Q30569574 |
| | Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group | Q33157410 |
| | On estimating efficacy from clinical trials | Q33523091 |
| | Cost-effectiveness analysis of hypertension treatment--a review of methodological issues. | Q33550061 |
| | Quality of life instruments in the evaluation of new drugs | Q33560213 |
| | Economic factors in the initiation of antihypertensive therapy | Q33560397 |
| | Cost of innovation in the pharmaceutical industry | Q33856950 |
| | The economic costs of illness: a replication and update | Q34313474 |
| | Projections of national health expenditures through the year 2000. | Q34320710 |
| | Payments to healthy volunteers--ethical problems | Q34358330 |
| | Cost and efficiency considerations in community-based trials of vitamin A in developing countries | Q34607463 |
| | Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials | Q35170262 |
| | Decision analysis in medicine | Q35821389 |
| | Review of company postmarketing surveillance studies | Q35821940 |
| | Do large, simple trials have a place in the evaluation of AIDS therapies? | Q35874800 |
| | Methodology of measuring the efficacy of antidepressants | Q35906870 |
| | Methodology of measuring the efficacy of antidepressants--European viewpoint | Q35906875 |
| | Clinical trials and clinical practice in the elderly. A focus on hypertension | Q36167904 |
| | Physiological changes due to age. Pharmacodynamic changes of drug action and implications for therapy | Q36465585 |
| | Are some antihypertensive therapies more efficacious than others in preventing complications and prolonging life? | Q36517387 |
| | Stimulants and antidepressant pharmacokinetics in hyperactive children | Q36550373 |
| | Statistical efficiencies that the FDA should encourage | Q36923924 |
| | To increase power in randomized clinical trials without increasing sample size | Q36923929 |
| | A note on randomization and selection bias in maintenance therapy clinical trials | Q36923933 |
| | Clinical factors that may confound the assessment of drug efficacy | Q36923938 |
| | Psychopharmacology of children and adolescents: pharmacokinetics and relationships of plasma/serum levels to response | Q37042582 |
| | Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: focus on women | Q37042585 |
| | Pharmacokinetic and other related factors affecting psychotropic responses in Asians | Q37042594 |
| | Psychopharmacologic considerations in the treatment of black American populations | Q37042595 |
| | Ethnic psychopharmacology: the Hispanic and Native American perspective | Q37042601 |
| | Interaction of ethanol and smoking on the pharmacokinetics and pharmacodynamics of psychotropic medications | Q37042635 |
| | Measuring the adverse effects of unnecessary hypertension drug therapy: QALYs vs HYE. | Q37303741 |
| | Measuring costs and financial benefits in randomized controlled trials | Q37808530 |
| | Clinical trials in the elderly. Pivotal points. | Q37919204 |
| | A progress report on reimbursement of biotherapy: prospects for the 1990s | Q38733926 |
| | Analysis of the costs of a large prevention trial | Q39260051 |
| | The Women's Health Trial as an investment | Q39273338 |
| | The changing face of clinical trials | Q39555546 |
| | Evaluation of quality of life in clinical trials of cardiovascular disease | Q39659263 |
| | Randomized vs. historical clinical trials. Are the benefits worth the cost? | Q39833600 |
| | Comparative pharmacokinetic changes and drug therapy in an older population. | Q40245100 |
| | An economic evaluation of asthma in the United States | Q41120870 |
| | Rising research and development costs for new drugs in a cost containment environment | Q41136013 |
| | Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials | Q41187186 |
| | Weight of financial reward in the decision by medical students and experienced healthy volunteers to participate in clinical trials | Q41201345 |
| | Who's paying for new drugs? | Q41280346 |
| | Planning a clinical trial with allowance for cost and patient recruitment rate | Q41435741 |
| | A cost-function approach to the design of reliability studies | Q41466506 |
| | The impact of DRGs on clinical research centers. A multi-institutional study | Q42135870 |
| | Advances in the treatment of chronic heart failure | Q42765112 |
| | Patients, profits, and progress. | Q43537618 |
| | Long-term mortality after 5-year multifactorial primary prevention of cardiovascular diseases in middle-aged men. | Q43808979 |
| | Use of cost-effectiveness analysis in planning cancer chemoprophylaxis trials | Q43821658 |
| | Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development | Q44021543 |
| | The crisis in clinical cancer research. Third-party insurance and investigational therapy. | Q44208114 |
| | Are prescription drug prices high? | Q44330100 |
| | Estimation of the design effect in community intervention studies | Q46851478 |
| | Planning the size and duration of a clinical trial studying the time to some critical event | Q47361312 |
| | Methodologic issues in maintenance therapy clinical trials. | Q52051116 |
| | Opportunities for enhancing efficiency and reducing cost in large scale disease prevention trials: a statistical perspective. | Q52501621 |
| | Choosing sample sizes to maximize expected health benefits subject to a constraint on total trial costs. | Q52546459 |
| | A method for predicting accrual, cost, and paper flow in clinical trials. | Q52589373 |
| | Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. | Q52863543 |
| | High risk subjects and the cost of large field trials. | Q52902275 |
| | Breakout II. Reimbursement concerns. | Q54194031 |
| | Differences in men and women in coronary artery disease, systemic hypertension and their treatment | Q67566668 |
| | Lomefloxacin: development of a once-a-day quinolone. Proceedings of a symposium. April 23-25, 1990, Miami, Florida | Q67847861 |
| | The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal | Q67916403 |
| | The latest report from Finland. A lesson in expectations | Q67941856 |
| | Compensation for medicine-induced injury in clinical trials | Q68718033 |
| | Cost and efficiency in clinical trials: the U.S. Physicians' Health Study | Q68798863 |
| | Reimbursement issues in cancer clinical trials | Q68800481 |
| | The Medical Outcomes Study. An application of methods for monitoring the results of medical care | Q69667944 |
| | Third-party reimbursement issues during a phase I trial of interleukin-2 | Q69736210 |
| | The cost to patients of participating in clinical trials | Q69943804 |
| | Clinical trials. Access and reimbursement | Q70113497 |
| | Who should pay? | Q70179838 |
| | Cost-effective priorities for cancer prevention | Q70435686 |
| | Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation | Q70911714 |
| | Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs) | Q74823115 |
| | Principles of pharmacoeconomic analysis of drug therapy | Q74823188 |
| | Long-term mortality after primary prevention for cardiovascular disease | Q93505595 |
| P433 | issue | 5 | |
| P304 | page(s) | 371-387 | |
| P577 | publication date | 1992-11-01 | |
| P1433 | published in | PharmacoEconomics | Q7180778 |
| P1476 | title | Optimising the economic efficiency of drug studies | |
| P478 | volume | 2 | |